117324-05-7

Basic information

• Product Name: ETHYL 2-AMINO-4-FLUOROBENZOATE
• Synonyms: ETHYL 2-AMINO-4-FLUOROBENZOATE
• CAS NO: 117324-05-7
• Molecular Formula: C₉H₁₀FNO₂
• Molecular Weight: 183.18
• Product Categories: Esters;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 117324-05-7.mol

Chemical Properties

• Boiling Point: 271.243 °C at 760 mmHg
• Flash Point: 117.844 °C
• Appearance: /
• Density: 1.219 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.46±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-AMINO-4-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-4-FLUOROBENZOATE(117324-05-7)
• EPA Substance Registry System: ETHYL 2-AMINO-4-FLUOROBENZOATE(117324-05-7)

Safety Data

• Hazardous Substances Data: 117324-05-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-AMINO-4-FLUOROBENZOATE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications due to its unique structural properties.
Used in Agrochemical Industry:
ETHYL 2-AMINO-4-FLUOROBENZOATE is used as a precursor in the production of agrochemicals, potentially enhancing crop protection and management through its incorporation into pesticides or other agricultural chemicals.
Used as an Anti-inflammatory Agent:
ETHYL 2-AMINO-4-FLUOROBENZOATE is used as an anti-inflammatory agent for its potential to reduce inflammation, which can be beneficial in treating a variety of conditions characterized by inflammation.
Used as an Analgesic Agent:
ETHYL 2-AMINO-4-FLUOROBENZOATE is used as an analgesic agent to help alleviate pain, making it a candidate for formulations in pain management therapies.

InChI:InChI=1/C9H10FNO2/c1-2-13-9(12)7-4-3-6(10)5-8(7)11/h3-5H,2,11H2,1H3

Upstream product

• 394-27-4 2-acetamido-4-fluorobenzoic acid 
• 446-32-2 4-fluoroanthranilic acid 
• 64-17-5 ethanol 

Downstream Products

• 473416-60-3 2-acetylamino-4-fluorobenzoic acid ethyl ester 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 1038343-02-0 C₁₇H₁₆FNO₃ 
• 1038343-01-9 C₁₆H₁₃ClFNO₃ 
• 1009368-27-7 2-(2-amino-4-fluorophenyl)propan-2-ol 
• 196194-86-2 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 199327-54-3 4-chloro-7-(2-methoxyethoxy)quinazoline 

Relevant articles and documents

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs

Fifty-two 2-benzoylaminobenzoate analogs were synthesized and subjected to anti-platelet aggregation assay using arachidonic acid (AA), collagen (Col), thrombin (Thr), and U46619 as inducers. The results revealed that most of 2-benzoylaminobenzoic acid derivatives showed a selectively inhibitory effect on AA-induced platelet aggregation. As a result of the 2-benzoylaminobenzoic acid derivatives (18, 44, and 46), there were no inhibitory effects on platelet aggregation induced by U46619, but these elicited an inhibitory effect on thromboxane B2 formation at 1.0 μM. These 2-benzoylaminobenzoate analogs were therefore proposed as cyclooxygenase inhibitors.

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

NOVEL 1H-INDAZOLE COMPOUND

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by -CO-NH- or -NH-CO-, etc.; and Y is a C3-C8 cycloalkyl group, a C6-C14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation. A series of highly potent, specific, orally active, small molecule kinase inhibitors directed against members of PDGFR receptor have been developed through modifications of the novel quinazoline template I. Systematic modifications in the A-bicyclic ring and D-rings of protype I were carried out to afford potent analogues, which display IC50 values of 50 values of 50-200 nM, whereas 15-20-fold less potent activity against CSF1R was observed. This analogue also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC50 values of 30-100 nM. Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T1/2 > 8 h). Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.

Quinazolin-4(3H)-one derivatives as anticoccidial agents

Variously substituted trans-3-[3-(3-hydroxypiperid-2-yl)-2-oxopropyl]quinazolin-4-(3H)-ones, a method of controlling or preventing coccidiosis in poultry therewith, intermediates therefor, and a process for the preparation of certain intermediates therefor.